Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
A lipoprotein is not a single molecule or receptor but rather a biochemical assembly composed of both lipid and protein that serves primarily to transport hydrophobic fat molecules—including cholesterol and triglycerides—in water-based environments such as blood plasma. The structure consists of an inner core containing non-polar lipids surrounded by an outer shell made up of phospholipids, unesterified cholesterol, and specialized proteins called apolipoproteins. These assemblies vary in size, density, composition, and function. There are several major classes based on density: chylomicrons; very-low-density lipoproteins (VLDL); intermediate-density lipoproteins (IDL); low-density lipoproteins (LDL); high-density lipoproteins (HDL). Each class has distinct roles in lipid metabolism—for example, - Chylomicrons carry dietary triglycerides from the intestines. - VLDLs deliver newly synthesized triglycerides from the liver. - LDLs distribute cholesterol throughout the body ("bad" cholesterol). - HDLs collect excess cholesterol for return to the liver ("good" cholesterol). Some subclasses like lipoprotein(a) [LP(a)] have unique clinical significance due to their association with increased cardiovascular risk. Because "lipoprotein" refers broadly to this family/class rather than any one molecular target or receptor—and because therapeutic drugs act on specific types/components—the term itself is not considered an individual therapeutic target but rather describes complexes that may contain targets such as apolipoproteins or receptors involved in their metabolism[3][1][7]. Therefore: The entry “Lipoprotein” is too broad/vague for use as a canonical drug target name. It should be replaced with more precise terms referring either to individual classes/subclasses (“Low-density lipoprotein”, “High-density lipoprotein”, “Lipoprotein(a)”) or their associated proteins/receptors (“Apolipoprotein B”, “Low-density-lipoprotein receptor”).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lipoprotein.